Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immuneering Corp Cl A
(NQ:
IMRX
)
1.900
-0.030 (-1.55%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immuneering Corp Cl A
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Friday's After-Market Session
October 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 15, 2024
Via
Benzinga
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 15, 2024
From
Immuneering Corporation
Via
GlobeNewswire
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
October 02, 2024
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar.
Via
Benzinga
Why is Immuneering (IMRX) Stock Up 24% Today?
August 01, 2024
Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus.
Via
InvestorPlace
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
September 13, 2024
Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response rate...
Via
Benzinga
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
September 12, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 06, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
August 01, 2024
Via
Benzinga
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
August 01, 2024
Via
Benzinga
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
July 31, 2024
From
Immuneering Corporation
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
June 11, 2024
Via
Benzinga
Immuneering to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Immuneering Corporation
Via
GlobeNewswire
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
May 07, 2024
IMRX stock results show that Immuneering missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
May 07, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Recognizes Melanoma Awareness Month
May 06, 2024
From
Immuneering Corporation
Via
GlobeNewswire
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
April 09, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
March 27, 2024
From
Immuneering Corporation
Via
GlobeNewswire
3 Stocks Insiders Are Buying That Analysts Love
March 26, 2024
Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits.
Via
MarketBeat
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
March 19, 2024
Via
AB Newswire
12 Health Care Stocks Moving In Monday's Intraday Session
March 18, 2024
Via
Benzinga
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 18, 2024
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates.
Via
Benzinga
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data
March 15, 2024
Immuneering shares dip as analysts express concern over IMM-1-104 trial results. Needham downgrades, citing efficacy issues despite promising mechanism of action. Optimism remains for earlier-stage...
Via
Benzinga
Dow Falls Over 200 Points; Adobe Shares Plunge
March 15, 2024
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded down 0.55% to 38,692.43 while the NASDAQ fell 0.90% to 15,982.65. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 15, 2024
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
March 15, 2024
Via
Benzinga
Crude Oil Edges Lower; US Consumer Sentiment Falls In March
March 15, 2024
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Friday. The Dow traded down 0.37% to 38,761.74 while the NASDAQ fell 0.95% to 15,974.83. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 14, 2024
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.